Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906
Open Access
- 30 January 2023
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (4) , 1011-1023
Abstract
Aim: To report two phase I studies of the novel subcutaneous glucagon‐like peptide‐1 receptor/glucagon receptor (GLP‐1R/GCGR) dual agonist BI 456906 versus placebo in healthy volunteers and people with overweight/obesity. Materials and Methods: A phase Ia study (NCT03175211) investigated single rising doses (SRDs) of BI 456906 in 24 males with a body mass index (BMI) of 20–2 . A phase Ib study (NCT03591718) investigated multiple rising doses (MRDs) of BI 456906 (escalated over 6 [Part A] or 16 [Part B] weeks) in 125 adults with a BMI of 27–40 kg/m 2 . Results: In the SRD study (N = 24), mean body weight decreased with increasing BI 456906 dose. In the MRD study, the maximum decreases in placebo‐corrected mean body weight were at week 6 (–5.79%, dosage schedule [DS] 1; Part A) and week 16 (–13.8%, DS7; Part B). BI 456906 reduced plasma amino acids and glucagon, indicating target engagement at GCGRs and GLP‐1Rs. Drug‐related adverse events (AEs) increased with BI 456906 dose. The most frequent drug‐related AE with SRDs was decreased appetite (n = 9, 50.0%), and two subjects (8.3%) did not complete the trial because of AEs (nausea and vomiting). During MRD Part A (N = 80), 10 subjects (12.5%) discontinued BI 456906, most commonly because of a cardiac or vascular AE (n = 6, 7.5%); during Part B (N = 45), eight subjects (17.8%) discontinued BI 456906, mainly because of AEs (n = 6, 13.3%), most commonly gastrointestinal disorders. Conclusions: BI 456906 produced a placebo‐corrected body weight loss of 13.8% (week 16), highlighting its potential to promote clinically meaningful body weight loss in people with overweight/obesity.Keywords
Funding Information
- Boehringer Ingelheim España
This publication has 49 references indexed in Scilit:
- Effects of GLP-1 on appetite and weightReviews in Endocrine and Metabolic Disorders, 2014
- Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of HyperglycemiaDiabetes, 2013
- Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdalaInternational Journal of Obesity, 2013
- The Glucagon Receptor Is Involved in Mediating the Body Weight‐Lowering Effects of OxyntomodulinObesity, 2012
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutideInternational Journal of Obesity, 2011
- Effects of central administration of glucagon on feed intake and endocrine responses in sheepAnimal Science Journal, 2009
- Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat dietAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trialInternational Journal of Obesity, 2006
- The definition of weight maintenanceInternational Journal of Obesity, 2005
- Peripheral Oxyntomodulin Reduces Food Intake and Body Weight Gain in RatsEndocrinology, 2004